Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
A DNA Methylation Based Blood Test for Prostate Cancer
FY 2016-17
Summary
Prostate cancer is the second highest cause of cancer related death worldwide. Prostate tumours can have varying degrees of aggressiveness. Treatments are invasive and can have complications. With each patient, the physician must determine whether to intervene and treat the tumour, or, if the tumour poses low risk of harm, to simply observe it. Current tools used by physicians answer these questions are limited. There remains the need to develop diagnostic tools for prostate cancer that allow for early cancer detection and prediction of clinical course of disease. A cell is composed of many molecules, including fats, proteins and DNA. As it becomes cancerous, the composition and nature of these molecules change. By identifying which biological molecules are signs of cancer, we can develop biomarkers, that, if found in the body, are indicative of the disease. To create biomarkers for prostate cancer, we propose identifying changes to DNA specifically, a phenomenon known as DNA methylation. Using DNA methylation can allow for specific prostate cancer detection; certain forms of DNA methylation only occur when a cell becomes cancerous, and are not found in other, non-life threatening conditions. In addition, DNA methylation can be easily assessed in blood, and can be used to predict prostate tumour aggressiveness. My research will involve determining the nature of DNA methylation in prostate tumours and creating and validating a novel blood test for prostate cancer based on these findings. If this test can be effectively created, more individuals with prostate cancer will be accurately identified and treated before the disease becomes fatal.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
367081
Name
Carson Jacob J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A DNA Methylation Based Blood Test for Prostate Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Blood Test; Circulating Tumour Dna; Dna Methylation; Early Detection; Prostate Cancer Diagnostic Test
Abstract
Prostate cancer is the second highest cause of cancer related death worldwide. Prostate tumours can have varying degrees of aggressiveness. Treatments are invasive and can have complications. With each patient, the physician must determine whether to intervene and treat the tumour, or, if the tumour poses low risk of harm, to simply observe it. Current tools used by physicians answer these questions are limited. There remains the need to develop diagnostic tools for prostate cancer that allow for early cancer detection and prediction of clinical course of disease. A cell is composed of many molecules, including fats, proteins and DNA. As it becomes cancerous, the composition and nature of these molecules change. By identifying which biological molecules are signs of cancer, we can develop biomarkers, that, if found in the body, are indicative of the disease. To create biomarkers for prostate cancer, we propose identifying changes to DNA specifically, a phenomenon known as DNA methylation. Using DNA methylation can allow for specific prostate cancer detection; certain forms of DNA methylation only occur when a cell becomes cancerous, and are not found in other, non-life threatening conditions. In addition, DNA methylation can be easily assessed in blood, and can be used to predict prostate tumour aggressiveness. My research will involve determining the nature of DNA methylation in prostate tumours and creating and validating a novel blood test for prostate cancer based on these findings. If this test can be effectively created, more individuals with prostate cancer will be accurately identified and treated before the disease becomes fatal.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Carson, Jacob J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~